Dana Kigitoviča

Dana Kigitoviča is an Assistant in the Department of Internal Diseases at Riga Stradins University, Faculty of Medicine, Latvia. Her research is deeply rooted in clinical medicine, with a strong focus on venous thromboembolism, pulmonary embolism, and chronic thromboembolic pulmonary hypertension. She actively contributes to international collaborative research through the RIETE Investigators group and leads nationally funded projects on right ventricular function and meldonium therapy.

Her research interests include:

• Venous Thromboembolism and risk stratification
• Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
• Right ventricular failure and functional assessment
• Pharmacological effects of meldonium
• Anticoagulant therapy and bleeding risk
• Clinical outcomes in elderly patients with thrombosis

Dana Kigitoviča's recent publications (2021–2025) reflect a consistent focus on thromboembolic diseases, anticoagulation safety, and cardiac function. Her work leverages large international registries like RIETE and integrates experimental models to explore mitochondrial and right ventricular responses. A key trend is the translational application of biochemical and pharmacological research to improve patient outcomes.

She has been involved in significant research projects, including:

• Novel biochemical and morphological factor analysis and influence in right ventricle function (Project leader, 2021–2022)
• Support for involving doctoral students in scientific research and studies (Expert, 2021–2023)
• Implementation of balloon pulmonary angioplasty for CTEPH (Participant, 2021–2023)

She mentors numerous doctoral students and has presented her findings at national and international scientific events, including oral presentations on meldonium and poster presentations on kidney transplantation outcomes. Her work has been featured in press and media, highlighting its public health relevance.